Excessive screen time for children linked to later heart health risks
The time children and teens spend video gaming, scrolling through social media or watching TV could be putting their future heart health at risk, a new study says.
Each additional hour of screen time is associated with an increase in heart risk factors like blood pressure, cholesterol and blood sugar levels, researchers reported today in the Journal of the American Heart Association.
"It's a small change per hour, but when screen time accumulates to three, five or even six hours a day, as we saw in many adolescents, that adds up," lead investigator David Horner, a researcher at the University of Copenhagen in Denmark, said in a news release.
"Multiply that across a whole population of children, and you're looking at a meaningful shift in early cardiometabolic risk that could carry into adulthood," Horner added.
For the study, researchers pooled data from more than 1,000 participants in two Danish studies of childhood health.
Each child received a heart health risk score based on factors like waist size, blood pressure, "good" HDL cholesterol, triglycerides and blood sugar, researchers said. Parents reported on the kids' screen time.
Every hour a child or teen spent glued to a screen caused those risk factors to tilt toward the bad, results showed.
A child's sleep patterns contributed to this risk, researchers added.
Both shorter sleep duration and hitting the sack later intensified the relationship between screen time and heart health risk, results show. Kids and teens who had less sleep showed significantly higher risk associated with the same amount of screen time.
"About 12% of the association between screen time and cardiometabolic risk was mediated through shorter sleep duration," Horner said. "These findings suggest that insufficient sleep may not only magnify the impact of screen time but could be a key pathway linking screen habits to early metabolic changes."
An artificial intelligence analysis found that kids' blood carried a set of markers -- what researchers called a "screen-time fingerprint" -- that could predict how much time they'd been spending with screens, researchers added.
"We also assessed whether screen time was linked to predicted cardiovascular risk in adulthood, finding a positive trend in childhood and a significant association in adolescence," Horner said. "This suggests that screen-related metabolic changes may carry early signals of long-term heart health risk."
Since this was an observational study, the research cannot prove a direct cause-and-effect relationship between screen time and heart health, researchers noted.
Nevertheless, pediatricians should consider a discussion of children's screen habits during regular check-ups, Horner said.
The results also highlight the importance of good sleep to a child's health, said Dr. Amanda Marma Perak, chair of the American Heart Association's Young Hearts Cardiovascular Disease Prevention Committee. Perak, who was not involved in this research, reviewed the findings.
"If cutting back on screen time feels difficult, start by moving screen time earlier and focusing on getting into bed earlier and for longer," said Perak, an assistant professor of pediatrics and preventive medicine at Northwestern University Feinberg School of Medicine in Chicago.
Parents also should be prepared to set a good example, she added in a news release.
"All of us use screens, so it's important to guide kids, teens and young adults to healthy screen use in a way that grows with them," Perak said. "As a parent, you can model healthy screen use -- when to put it away, how to use it, how to avoid multitasking. And as kids get a little older, be more explicit, narrating why you put away your devices during dinner or other times together."
It's also important to teach kids how to entertain themselves without a screen, and to handle the discomfort that comes with boredom, Perak said.
"Boredom breeds brilliance and creativity, so don't be bothered when your kids complain they're bored," Perak said. "Loneliness and discomfort will happen throughout life, so those are opportunities to support and mentor your kids in healthy ways to respond that don't involve scrolling."
More information
Johns Hopkins Medicine has more on the effects of screen time on children.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
13 hours ago
- Miami Herald
A Wonder Drug Bungles Its Lead
EDITORS NOTE: EDS: REPEATING to RECODE as a Page 1 refer.); (ART ADV: With illustration.); (With: WEIGHT-LOSS-PILL For years, there was no stopping Novo Nordisk, the Danish drugmaker behind Ozempic. Its diabetes drug became a cultural phenomenon for its ability to induce drastic weight loss while also reducing the risk of heart attacks and other serious diseases in people with obesity. Its potential to transform the health care industry made it a darling of the stock market, surging to become the most valuable company in Europe. Then, suddenly, its fortunes took a turn. Novo Nordisk's share price has plummeted more than 50% this year, pushing it out of the Top 10 list of Europe's most valuable companies. The company bewildered analysts in May when it abruptly said it would replace its CEO, and it has seemed unable to keep ahead of competition from American drugmaker Eli Lilly and the prevalence of cheap copycat versions. "The market's got no patience for Novo," said Gareth Powell, the head of health care at Polar Capital, a fund manager. "Sentiment is absolutely dire." It has been a stunning reversal for the company behind a drug that physicians once called a game changer. On Wednesday, Novo Nordisk reported $24 billion in global sales in the first six months of the year, but reiterated that it expects growth to slow in the rest of the year, which it first flagged in a profit warning last week. The company's stock tumbled more, as analysts and investors expressed doubts about whether there was much the company could do to revive its prospects in the short term. Novo Nordisk is "a company with incredible history and capabilities, and they've got a pipeline," Powell said. "It's just the market's putting zero value on it." The Ozempic boom opens a 'can of worms' Novo Nordisk spent nearly a century in relative obscurity, known mostly to diabetes patients and physicians as the producer of half the world's insulin. That changed with Ozempic, the brand name for semaglutide, Novo Nordisk's synthetic version of a hormone known as glucagon-like peptide 1, or GLP-1, which helps the body regulate blood sugar levels. Ozempic, which came onto the market in late 2017, led to substantial weight loss and quickly attracted cultural cachet, not least because of its use among celebrities. TikTok videos documenting people's journey with Ozempic attracted millions of views. Analysts predicted that it could tap into an enormous market, since 1 billion people in the world are considered obese. In the first half of the year, Novo Nordisk made $10 billion in sales from Ozempic, of which 70% was in the United States. For a company that had been focused on the steady business of selling insulin, the popularity of Ozempic took its executives by surprise. In 2021, they started selling Wegovy, semaglutide marketed specifically for weight loss, but demand was so high that the company struggled to meet it. That shortage "opened a whole can of worms," said Rajesh Kumar, an analyst at HSBC. An FDA decision opens the door for copycats In 2022, semaglutide landed on the Food and Drug Administration's shortage list, which spurred production of cheaper copycat versions of Novo Nordisk's drugs. To ensure the supply of medicines facing shortages, U.S. federal law allows companies to produce versions of patented drugs via a process of mixing ingredients called compounding. The FDA said this year that the shortage was over and ordered producers and sellers of the copycat weight-loss drugs to wind down. But Novo Nordisk said that never happened. Compounders have continued to offer what they call "personalized" versions of the drugs, a legally murky practice that they claim is allowed by the law. Novo Nordisk said last week that more than 1 million people were still using compounded GLP-1s, eating into the company's market share and forcing it to slash sales and profit forecasts. Its shares promptly dropped more than 20%, erasing more than $70 billion in market value in a day, and some analysts lowered their recommendations on the company. One of them was Kumar, who had been advising investors buy Novo Nordisk's shares for at least two years before downgrading last week to "hold." Compounding was part of the reason. "Novo is issuing a lot of cease-and-desist orders, but it has been very difficult to stop them," he said, adding that he had never seen compounding at this scale before. On Wednesday, Novo Nordisk said it had filed 14 new lawsuits against compounders the day before. "It's important that we get compounding off the market because right now it has equal size of our business," said Lars Fruergaard Jorgensen, the departing CEO. Compounders, in particular, have targeted Wegovy because it was the most well-known brand, Kumar said. That has helped Eli Lilly to get an edge. Eli Lilly catches up, and then some Novo Nordisk had a huge head start. After Ozempic went on sale, it was another 4 1/2 years before a serious competitor emerged: Eli Lilly's Mounjaro, the brand name for tirzepatide, a drug used to treat diabetes. Mounjaro proved to be more effective, leading to greater weight loss in clinical trials. Many patients said they preferred it. At the start of this year, Eli Lilly's Zepbound, which is tirzepatide marketed for weight loss, passed Wegovy in new prescriptions in the United States, according to IQVIA, an analytics company. Unlike Novo Nordisk, Eli Lilly also found ways to get its product to consumers more cheaply, and compete with telehealth companies offering compounded copycat versions, by selling its drug in vials with syringes instead of the more expensive pens with prefilled doses. Novo Nordisk was further hampered by its slowness in introducing a direct-to-consumer sales platform. NovoCare Pharmacy launched in March, 14 months after LillyDirect. "Lilly was doing all these things, and Novo wasn't," said Emily Field, an analyst at Barclays, who recently downgraded the stock. "It felt like a lot of this was one big own goal," she said. Novo's pipeline struggles to impress More than anything, a company's market value is determined by investors' expectations for earnings in the future. For a pharmaceutical company, that means the drugs in its pipeline. This has helped Eli Lilly's stock outperform Novo Nordisk's this year. Investors and analysts are particularly interested in the prospects of weight-loss pills, which could reach more patients than injections. Eli Lilly's daily pill, orforglipron, has been showing promising results in late-stage clinical trials, with similar weight loss to Novo Nordisk's injections and fewer restrictions on its use. Novo Nordisk's oral tablet leads to less weight loss than its injections, but the company has other pills in development. On Thursday, Eli Lilly said that its orforglipron tablets led to 12% weight loss, slightly less than analysts expected, which dented Eli Lilly's shares and gave Novo Nordisk's a boost. But Eli Lilly also raised its overall earnings forecast for the year, on greater demand for Zepbound. In developing its pipeline, Eli Lilly is "deploying capital and running faster than Novo in a market that isn't going to be patient in any way," said Seamus Fernandez, an analyst at Guggenheim Partners. Can a new leader make a difference? The Novo Nordisk Foundation, which controls Novo Nordisk through its holding company, has also grown impatient. At the foundation's urging, Jorgensen, who had been CEO of the company since Ozempic came onto the market, stepped down. Maziar Mike Doustdar took over the top role Thursday, the first non-Dane to run the company. Doustdar, an Iranian-born Austrian citizen who grew up in the United States, joined the company in 1992, for what he thought would be a summer job making photocopies. "He has a bias for speed, for pace and for action," Helge Lund, the chair of the board of directors, said when announcing Doustdar's appointment. Concerns are mounting that analysts may have overestimated the potential size of the weight-loss market, or at least how easily more people will gain access to these drugs. At the same time, President Donald Trump is pressuring companies to lower drug prices and threatening tariffs on medicines produced abroad, casting a cloud over pharma firms' business models. "I still believe there's a big market," said Powell of Polar Capital, which invests in both Novo Nordisk and Eli Lilly. But broad concerns about the market are hitting Novo Nordisk hardest, he added. There probably isn't anything a new CEO could do to "dramatically change" the outlook in the next one or two years, Powell said. "The reality is what it is," he said. "Lilly's product is seen as better." This article originally appeared in The New York Times. Copyright 2025
UPI
15 hours ago
- UPI
Pistachios, Dubai Chocolate linked to Canadian salmonella outbreak
The symptoms of salmonella (pictured under a microscope), typically appear six to 72 hours after exposure. File Image by Alissa Eckert, James Archer/CDC Aug. 7 (UPI) -- An ongoing outbreak of salmonella in Canada has been linked to pistachios, including those found in some Dubai Chocolate. The Canadian Food Inspection Agency announced the recall of certain pistachio brands and products that contain pistachios. The Public Health Agency of Canada followed up with a notice about an outbreak of salmonella. The brands recalled are: Dubai Chocolate is a popular brand that got lots of attention on Instagram and TikTok in 2024. "While no illnesses have been reported from this specific chocolate, the product contains pistachios that could be linked to the outbreak," the CFIA said. As of Wednesday, there were 52 confirmed patients: 39 in Quebec, nine in Ontario, three in British Columbia and one in Manitoba, according to Public Health Canada. Nine of the patients have been hospitalized. The patients range in age from 2- to 89-years-old. People became sick between early March and mid-July, Food Safety News reported. The PHAC is investigating two strains of the bacteria, Salmonella Havana and Salmonella Mbandaka, that have been identified in the national outbreak. Officials said the actual number of cases may be much higher due to underreporting, the Economic Times reported. Salmonella symptoms typically appear six to 72 hours after exposure. They include fever, chills, diarrhea, nausea, vomiting, and abdominal cramps. Healthy people usually recover without treatment, but infants, seniors, pregnant women, and those with weakened immune systems are at higher risk for severe complications. The CFIA said anyone who bought the recalled chocolate should throw it out or return it to where they bought it. Anyone who believes they may have become ill after eating the product should seek medical attention. Gulf News clarified that the name of the chocolate does not indicate that the pistachios or the final product were sourced from Dubai or the UAE. The country of origin has not been released.
UPI
19 hours ago
- UPI
EU climate service says July 2025 third warmest on record
The European Commission's weather service said July 2025 was the third warmest month ever recorded. Photo by John Angelillo/UPI | License Photo Aug. 7 (UPI) -- The European Commission's weather service said July 2025 was the third warmest month ever recorded. The global average temperature in July 2025 was 62 degrees Fahrenheit, behind only July 2023 and July 2024, according to the Copernicus Climate Change Service. It was 34.25 degrees Fahrenheit above the pre-industrial average. The last 12 months, taken together, were also 34.75 degrees Fahrenheit above the pre-industrial level. "Two years after the hottest July on record, the recent streak of global temperature records is over for now," Director of the Copernicus Climate Change Service Carlo Buontempo said. "But this doesn't mean climate change has stopped. We continued to witness the effects of a warming world in events such as extreme heat and catastrophic floods in July. Unless we rapidly stabilize greenhouse gas concentrations in the atmosphere, we should expect not only new temperature records but also a worsening of these impacts -- and we must prepare for that." The average temperature over land was 70.25 degrees Fahrenheit, which is 34.34 degrees above the 1991-2020 average for July. "Global warming isn't going away; it will get stronger in the decades ahead, so the summer of 2025 is a clear illustration of how things will be," a researcher at the Norwegian climate research institution Cicero, Bjorn Samset, said.
